RxDoctor Payments Data

Timothy Mahaney, APRN

Psychiatric/Mental Health · Fort Myers, FLNPI 1386329514

Payments from drug & device makers

$812in general payments, 2019–2025

Across 25 payments — averaging $32.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$220
  • Neurocrine Biosciences, Inc.$210
  • Otsuka America Pharmaceutical, Inc.$194
  • Almatica Pharma LLC$108
  • Axsome Therapeutics, Inc.$38
  • Johnson & Johnson$22
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$812100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$812 in reported general payments places this provider in the 50th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$61,012
Medicare patients
169
Services billed
593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine12$200,270
Invega SustennaPaliperidone Palmitate25$78,238
VraylarCariprazine Hcl25$40,070
Abilify MaintenaAripiprazole13$32,689
Aripiprazole151$15,282
TrintellixVortioxetine Hydrobromide30$14,066
Lurasidone Hcl62$14,025
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl59$11,961
Ziprasidone Hcl153$11,359
Quetiapine Fumarate499$7,573
Trazodone Hcl582$7,435
Bupropion XlBupropion Hcl515$7,357
Oxcarbazepine95$7,109
Duloxetine Hcl259$5,682
Clonazepam451$4,493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$220$200,27012 claims
Johnson & JohnsonInvega Sustenna$22$78,23825 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$194$32,68913 claims
Almatica Pharma LLCSertraline Hcl$108$1,347262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →